Markets Analysts start Castle Biosciences at buy and OP with PTs of $25-to-$28 Analysts for SVB Leerink, BTIG and Canaccord Genuity launched coverage of Castle Biosciences (NASDAQ:CSTL), saying the company answers a large unmet need in skin cancer. The stock closed at $20.25 on Aug. 16. SVB... August 19, 2019